0001493152-23-024684.txt : 20230717
0001493152-23-024684.hdr.sgml : 20230717
20230717121036
ACCESSION NUMBER: 0001493152-23-024684
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20230717
DATE AS OF CHANGE: 20230717
EFFECTIVENESS DATE: 20230717
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sonnet BioTherapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001106838
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 522102141
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-487073
FILM NUMBER: 231091000
BUSINESS ADDRESS:
STREET 1: 100 OVERLOOK CENTER
STREET 2: SUITE 102
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-375-2227
MAIL ADDRESS:
STREET 1: 100 OVERLOOK CENTER
STREET 2: SUITE 102
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: Chanticleer Holdings, Inc.
DATE OF NAME CHANGE: 20050510
FORMER COMPANY:
FORMER CONFORMED NAME: TULVINE SYSTEMS INC
DATE OF NAME CHANGE: 20000214
D
1
primary_doc.xml
X0708
D
LIVE
0001106838
Sonnet BioTherapeutics Holdings, Inc.
100 OVERLOOK CETNER
SUITE 102
PRINCETON
NJ
NEW JERSEY
08540
609-375-2227
DELAWARE
Tulvine Systems Inc
Chanticleer Holdings, Inc.
TULVINE SYSTEMS INC
Corporation
true
Pankaj
Mohan
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Director
Jay
Cross
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Executive Officer
John
K.
Cini
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Susan
Dexter
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Richard
Kenny
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Executive Officer
Nailesh
Bhatt
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Director
Albert
Dyrness
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Director
Donald
Griffith
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Director
Raghu
Rao
100 Overlook Center
Suite 102
Princeton
NJ
NEW JERSEY
08540
Director
Biotechnology
Decline to Disclose
- 06b
false
2023-06-30
false
true
true
true
false
0
Chardan Capital Markets, LLC
120128
None
None
17 STATE STREET
SUITE 2130
NEW YORK
NY
NEW YORK
10004
All States
false
2250000
2250000
0
false
1
226250
0
0
true
The Company shall use the net proceeds from the sale for working capital purposes.
false
Sonnet BioTherapeutics Holdings, Inc.
/s/ Jay Cross
Jay Cross
Chief Financial Officer
2023-07-17